Price
427.3
+2.49%52W Range
Market Cap
₹2,366.99 Cr
Traded: ₹3.07 Cr (0.13%) 0.0x
Free Float: ₹349.37 Cr (0.88% of FF traded)
Volume · 60D trend
72.7 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | +13.0% | +12.0% | -- | -- | Decelerating |
| Return | -- | -21.0% | -17.0% | -32.0% | -- | Stable |
| Profit | -- | +11.0% | +8.0% | -- | +12.0% | Stable |
| Sales | -- | +28.0% | +13.0% | -- | +20.0% | Stable |
Quarterly Results
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Sep 2026PDF ↗ | Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 698 | 697 | 685 | 582 | 586 | 544 | 580 | 513 | 498 | 490 | 473 | 464 | 483 | 411 | 406 | 389 |
| Expenses | 611 | 617 | 608 | 513 | 514 | 476 | 510 | 448 | 432 | 425 | 409 | 400 | 420 | 353 | 352 | 335 |
| Operating Profit | 87 | 81 | 77 | 69 | 72 | 68 | 69 | 65 | 66 | 65 | 64 | 64 | 64 | 58 | 55 | 54 |
| Other Income | 1 | 4 | 20 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 4 | 1 | 2 | 3 | 1 |
| Interest | 9 | 11 | 9 | 8 | 6 | 6 | 6 | 5 | 4 | 4 | 3 | 4 | 5 | 6 | 4 | 5 |
| Depreciation | 30 | 26 | 24 | 20 | 18 | 18 | 18 | 18 | 15 | 15 | 16 | 15 | 15 | 14 | 16 | 16 |
| Profit Before Tax | 49 | 48 | 64 | 43 | 50 | 46 | 48 | 42 | 48 | 47 | 46 | 48 | 45 | 39 | 37 | 35 |
| Tax % | 21.0% | 26.0% | 28.0% | 23.0% | 26.0% | 27.0% | 28.0% | 25.0% | 27.0% | 26.0% | 25.0% | 28.0% | 26.0% | 26.0% | 22.0% | 26.0% |
| Net Profit | 39 | 35 | 46 | 33 | 37 | 34 | 34 | 32 | 35 | 35 | 34 | 34 | 33 | 29 | 29 | 26 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 7.0 | 6.3 | 8.3 | 5.9 | 6.7 | 6.1 | 6.2 | 5.7 | 6.4 | 6.3 | 6.2 | 6.2 | 6.0 | 5.3 | 5.3 | 4.7 |
| Sales Growth (YoY) | 19.1% | 28.1% | 18.1% | 13.4% | 17.7% | 11.0% | 22.6% | 10.6% | 3.1% | 19.2% | 16.5% | 19.3% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 0.1% | 1.8% | 17.7% | -0.7% | 7.7% | -6.2% | 13.1% | 3.0% | 1.6% | 3.6% | 1.9% | -3.9% | 17.5% | 1.2% | 4.4% | -- |
| OP Growth (YoY) | 20.8% | 19.1% | 11.6% | 6.2% | 9.1% | 4.6% | 7.8% | 1.6% | 3.1% | 12.1% | 16.4% | 18.5% | -- | -- | -- | -- |
| OP Growth (QoQ) | 7.4% | 5.2% | 11.6% | -4.2% | 5.9% | -1.4% | 6.2% | -1.5% | 1.5% | 1.6% | 0.0% | 0.0% | 10.3% | 5.5% | 1.9% | -- |
| Profit Growth (YoY) | 5.5% | 4.5% | 33.5% | 3.4% | 4.4% | -3.7% | 0.9% | -7.8% | 7.2% | 19.4% | 17.8% | 33.9% | 37.8% | 1.9% | 20.4% | 12.6% |
| EPS Growth (YoY) | 5.4% | 4.5% | 33.4% | 3.3% | 4.2% | -4.0% | 0.7% | -8.0% | 7.0% | 19.3% | 17.7% | 33.7% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 10.7% | -23.6% | 40.2% | -11.1% | 9.7% | -2.4% | 8.6% | -10.3% | 1.1% | 2.3% | -0.8% | 4.4% | 12.6% | 0.9% | 12.7% | -- |
| OP Margin | 12.5% | 11.6% | 11.2% | 11.9% | 12.3% | 12.5% | 11.9% | 12.7% | 13.3% | 13.3% | 13.5% | 13.8% | 13.3% | 14.1% | 13.6% | 13.9% |
| Net Margin | 5.6% | 5.0% | 6.7% | 5.7% | 6.3% | 6.3% | 5.9% | 6.2% | 7.0% | 7.1% | 7.2% | 7.3% | 6.8% | 7.1% | 7.1% | 6.7% |
| Material Cost % | 68.0% | 70.0% | 72.0% | 69.0% | 68.0% | 68.0% | 69.0% | 68.0% | 68.0% | 70.0% | 72.0% | 70.0% | 71.0% | 71.0% | 70.0% | 70.0% |
| Employee Cost % | 6.0% | 6.0% | 6.0% | 7.0% | 6.0% | 7.0% | 6.0% | 7.0% | 7.0% | 6.0% | 5.0% | 6.0% | 6.0% | 6.0% | 7.0% | 6.0% |
| P/S | 0.89 | 0.99 | 1.23 | 1.22 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 15.49 | 16.70 | 19.72 | 20.27 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.68 | 1.89 | 2.21 | 2.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Intimation of Transcript of Q2 & H1 FY27 for the Earnings Conference Call held on October 19, 2026
Audio recording of Earnings Conference Call for Q2 & H1 FY 27.
Press Release for Q2 FY27 Results
Intimation of Q2 & H1 FY27- Earnings Presentation
Newspaper publication of extract of Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half year ended September 30, 2026.
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Outcome of Board Meeting Held On October 17, 2026
Intimation of Earnings Conference Call for investor and analyst on Monday, October 19, 2026 at 04:00 P.M. (IST).
Rossari Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/10/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026
Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.
Intimation of Analyst/Institutional Investors Meet/Con. Call/Updates.
Intimation of non-participation in the investors and analysts meet scheduled on Monday, August 10, 2026.
Intimation of Transcript of Q1 FY 27 for the Earnings Conference Call held on July 20, 2026.
Scrutinizer''s Report for the 17th Annual General Meeting of the Members of the Company.
Outcome of 17th Annual General Meeting of the Members of the Company along with Proceedings, Voting Results and Scrutinizers Report.
Rossari Biotech Limited informed the Exchange regarding Press Release dated July 18, 2026 titled " Rossari Biotech Limited announces Q1 FY 27 results".
Intimation of Q1 FY27- Earnings Presentation.
Newspaper publication of extract of Consolidated Unaudited Financial Results for the quarter ended June 30, 2026.
Unaudited Financial Results (standalone and consolidated) for the quarter ended June 30, 2026
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Intimation of grant of 4000 options Under Rossari Employee Stock Option Plan - 2019
Intimation of allotment of 2500 Equity Shares under Rossari Employee Stock Option Plan - 2019
Board Meeting held on Saturday, July 18, 2026
Intimation of Earnings Conference Call for investor and analyst on Monday, July 20, 2026 at 05:00 P.M. (IST).
Rossari Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/07/2026 ,inter alia, to consider and approve Unaudited Financial Results ....
Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026
Newspaper Publication of Notice of 17th Annual General Meeting of the Company and details relating to E-voting facility
Business Responsibility and Sustainability Report for the Financial Year 2025-26.
Annual Report for the Financial Year 2025-26.
Intimation regarding dispatch of letters to non-email shareholders.
Intimation of 17th Annual General Meeting ("AGM") of the Company to be held on Monday, July 20, 2026 at 11:00 A.M. (IST) through Video Conferencing/ Other Audio Visual Means ("VC/OAVM").
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Rossari Biotech Limited has informed the Exchange regarding the Trading Window Closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.
Newspaper publication of Notice of information regarding the 17th Annual General Meeting of the Company scheduled to be held on Monday, July 20, 2026.
Rossari Biotech Limited informed the Exchange that Record date for the purpose of Final Dividend is Friday, July 10, 2026 and Cut off date for E-voting is Monday, July 13, 2026.
The Annual General Meeting of the Company is scheduled to be held on Monday, July, 20, 2026.
Intimation of Analyst/ Institutional Investor Meet/ Con. Call/Updates.
Annual Secretarial Compliance Report for the Financial Year 2025-26.
Re-appointment of Ms. Esha Padmanabhan Achan (DIN:10350369), as a Non-Executive Independent Director of the Company.
Intimation of grant of 830050 options under Rossari Employee Stock Option Plan- 2019.
Outcome of Board Meeting held on May 27, 2026
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.
Intimation of Transcript of Q4 FY 26 for the Earnings Conference Call held on April 28, 2026.
Newspaper Publication of extract of Consolidated Audited Financial Results for the Quarter and Financial Year ended March 31, 2026.
Rossari Biotech Limited informed the Exchange regarding Press Release dated April 27, 2026 titled " Rossari Biotech announces Q4 FY 26 results".
Intimation of Q4 FY26- Earnings Presentation.
Intimation of completion of tenure of Ms. Aparna Sharma (DIN:07132341) as an Independent Director of the Company from the close of business hours of April 28, 2026.
Audio recording of Earnings Conference Call for Q4 FY 26.
Credit Ratings
5Concalls
28Jan 2026
31 Jan 2026Oct 2025
31 Oct 2025Jul 2025
31 Jul 2025May 2025
31 May 2025Jan 2025
31 Jan 2025Oct 2024
31 Oct 2024Oct 2024
31 Oct 2024Jul 2024
31 Jul 2024May 2024
31 May 2024Jan 2024
31 Jan 2024Oct 2023
31 Oct 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Oct 2021
31 Oct 2021Aug 2021
31 Aug 2021Jul 2021
31 Jul 2021Jun 2021
30 Jun 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Oct 2020
31 Oct 2020Aug 2020
31 Aug 2020Held by Mutual Funds
6 schemes hold rossari · sorted by weight